Trial Profile
An Interventional Phase II Study to Analyze the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- Acronyms PEMSYS
- 17 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record